Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · IEX Real-Time Price · USD
1.320
+0.010 (0.76%)
At close: Jul 19, 2024, 4:00 PM
1.280
-0.040 (-3.03%)
Pre-market: Jul 22, 2024, 7:15 AM EDT
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $31.12M in the twelve months ending March 31, 2024, with 0.95% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $2.40M. In the year 2023, Aclaris Therapeutics had annual revenue of $31.25M with 5.03% growth.
Revenue (ttm)
$31.12M
Revenue Growth
+0.95%
P/S Ratio
3.02
Revenue / Employee
$341,967
Employees
91
Market Cap
94.07M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
Dec 31, 2018 | 6.15M | 4.47M | 265.48% |
Dec 31, 2017 | 1.68M | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
111, Inc. | 2.05B |
Xtant Medical Holdings | 101.23M |
Sensus Healthcare | 31.66M |
Asensus Surgical | 8.72M |
Sagimet Biosciences | 2.00M |
Checkpoint Therapeutics | 68.00K |
ACRS News
- 5 days ago - Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million - GlobeNewsWire
- 26 days ago - Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte) - GlobeNewsWire
- 6 weeks ago - Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - American Clinical Research Services Announces Strategic Acquisition of Elixia - Business Wire
- 2 months ago - Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer - PRNewsWire
- 5 months ago - Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 months ago - Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis - GlobeNewsWire